Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Prospective Study to Assess Efficacy of Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy With High Preoperative Pulmonary Vascular Resistance

Next Previous
Trial Profile

A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Prospective Study to Assess Efficacy of Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy With High Preoperative Pulmonary Vascular Resistance

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2018

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary hypertension
  • Focus Therapeutic Use
  • Acronyms PEA Bridging Study

    • Most Recent Events

    • 12 Sep 2018 Status changed from not yet recruiting to recruiting.
    • 31 Aug 2018 Biomarkers information updated
    • 04 Jul 2018 Planned End Date changed from 1 Feb 2020 to 1 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top